Thus, it appears that controlling the CH morphology allows controlling the CH phenotype by utilizing the fact that modulating the actin cytoskeleton impacts on the FAK activity level, which subsequently controls SF formation vs. disassembly and determines the balance between insufficient vs. abundant SOX9 phosphorylation. The gene discussed is PTK2; the disease is cyclic hematopoiesis.